Home Reports Life Sciences Content

Differences in chemokine receptors and chemokines in erythroderma and Sézary syndrome

next article

20.12.2006

This study, published in the journal "Dermatology", evaluates chemokine release (TARC, MDC, IP-10) and defines the expression pattern of Th1- (CCR5, CXCR3) and Th2-related (CCR4) chemokine receptors in inflammatory erythroderma and Sézary syndrome.

Erythroderma can be caused by inflammatory dermatoses or cutaneous T-cell lymphoma. However, even if chemokines and their receptors are involved in the skin-selective lymphocyte recruitment, their role in inflammatory erythroderma is yet unclear.

Flow cytometry was carried out on both circulating and skin-infiltrating T lymphocytes, and serum chemokine levels were evaluated using ELISA techniques. CCR4, CCR5 and CXCR3 were expressed on about 40% of peripheral blood lymphocytes and on the majority of skin-infiltrating lymphocytes in the inflammatory erythroderma patients, whereas the leukemic CD4+CD26- subpopulation in Sézary syndrome was characterized by a high CCR4 expression without a concurrent increase in CCR5 or CXCR3. TARC, MDC and IP-10 serum levels were significantly increased in both erythrodermic and Sézary syndrome patients.

The results confirm that Sézary syndrome is a Th2 disorder with a selective expression of CCR4, whereas inflammatory erythroderma shares an overexpression of both Th1- and Th2-related chemokine receptors, suggesting an activation of different pathways driving reactive lymphocytes to the skin.

Carla Holmes | Source: alphagalileo
Further information: www.karger.com

next article